Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52616 | 0.99 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL52657 | 0.97 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL52067 | 0.81 | HTR7 (0.35) | SIGMAR1HTR7 | |
| SCHEMBL51655 | 0.80 | SIGMAR1 (0.34) | SIGMAR1 | |
| SCHEMBL51659 | 0.78 | MEN1 (0.38) | SIGMAR1HTR7 | |
| SCHEMBL2168243 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C19SIGMAR1 | |
| SCHEMBL52356 | 0.69 | CYP3A4 (0.32) | ALDH1A1SIGMAR1 | |
| SCHEMBL652976 | 0.68 | HTR7 (0.60) | HTR7 | |
| SCHEMBL51394 | 0.67 | USP2 (0.31) | — | |
| SCHEMBL52615 | 0.66 | S1PR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426596-B2 | Process of producing bleach boosters | BASF AKTIENGESELLSCHAFT (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8129531-B2 | Using an isoquinoline compound; alkylation of benzonitrile; reduction ofnitrile to an amine; cyclization | BASF AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110319622-A1 | PROCESS OF PRODUCING BLEACH BOOSTERS | BASF SE (DE) | 2011-12-29 | — | — | US | disclosed |
| EP-1891192-B1 | ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY | PROCTER & GAMBLE (US) | 2009-12-16 | — | — | EP | disclosed |
| US-20090149366-A1 | ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY | MIRACLE GREGORY SCOT | 2009-06-11 | — | — | US | disclosed |
| US-20080214819-A1 | Process of Producing Bleach Boosters | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1891192-A1 | ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY | The Procter and Gamble Company (US) | 2008-02-27 | — | — | EP | disclosed |
| US-20070197421-A1 | Organic catalyst with enhanced enzyme compatibility | PROCTER & GAMBLE COMPANY, THE | 2007-08-23 | — | — | US | disclosed |
| WO-2007001261-A1 | ORGANIC CATALYST WITH ENHANCED ENZYME COMPATIBILITY | THE PROCTER & GAMBLE COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214819-A1 | Process of Producing Bleach Boosters | SQLE, BCHE, CAT | ALDH1A1 1143/4885CYP1A2 48/4885CYP2D6 531/4885 |
| US-20110319622-A1 | PROCESS OF PRODUCING BLEACH BOOSTERS | SQLE, BCHE, CAT | ALDH1A1 1143/4885CYP1A2 48/4885CYP2D6 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.